Private endocrine consultations in LondonCall the practice: 020 3098 3881
Dr Daniel MorgansteinConsultant EndocrinologistRequest an appointment

About Dr Morganstein

Knowledge built on experience and research.

Consultant Endocrinologist at Chelsea and Westminster and The Royal Marsden hospitals and Honorary Clinical Senior Lecturer at Imperial College, with a special interest in endocrine oncology.

Dr Daniel Morganstein studied at Cambridge and qualified from St Bartholomew's and the Royal London in 1998. He trained in endocrinology and diabetes on the Hammersmith Rotation and undertook research at Imperial College London, where he attained his PhD.

He is experienced in all aspects of diabetes and endocrinology. His particular interests include endocrine tumours such as neuroendocrine tumours, adrenal tumours and paragangliomas; thyroid cancer, including medullary thyroid cancer; and the management of diabetes and hormonal effects during cancer treatment.

His further clinical interests include type 2 diabetes, pituitary and parathyroid disease. Dr Morganstein also provides diabetes and endocrinology services to several institutions and has published numerous scientific papers.

Dr Morganstein has been an invited speaker at a number of national and international scientific meetings including the British Endocrine Society, the European Endocrine Society, the European Association for Study of Diabetes and Diabetes UK Professional Conference.

Qualifications

MA (Cantab), FRCP, PhD

Professional registration

General Medical Council · 4518925

Consulting locations

Hospital locations in London

Dr Morganstein provides services at the following hospitals.

Selected publications

Dr Morganstein's work spans endocrine oncology, diabetes in cancer care, thyroid disease and the management of hormone-related complications of cancer treatment.

2026

Griffiths, B., S. Mehar, M. Blangiardo, A. Bottle, S. Misra, D. Morganstein, T. Willis and E. Gregg.“Evaluating the Effectiveness of the Reducing Weight With Intensive Dietary Support (REWIND) Programme on Type 2 Diabetes Remission”.Diabetes Obes Metab.

2026

Mohamed, E., R. Eeles, T. McVeigh and D. Morganstein.“To screen or not to screen: complexity of SDHA mutation management”.Endocr Oncol, 6(1): e250048.

2025

Cheng, L., S. K. Ghaznavi, J. Stevens, S. Hoy, K. H. Wong, T. Malik, K. Newbold and D. Morganstein.“Acute severe hypocalcaemia after initiation of a selective RET-inhibitor in medullary thyroid cancer”.Endocr Oncol, 5(1): e240060.

2025

Igbinosa, E., B. Dharmasekara, J. Quint, S. Popat, K. Bhaskaran, D. Morganstein and S. Cook.“Mortality Outcomes in People with Lung Cancer with and without Type 2 Diabetes: A Cohort Study in England”.Clinical Epidemiology, Volume 17: 681-692.

2025

Khurshed, A., G. Hernandez, G. Soady, N. Joharatnam-Hogan and D. Morganstein.“Using routinely collected patient data to study the impact of type 2 diabetes on breast cancer”.Endocr Oncol, 5(1): e240039.

2025

Massen, G. M., S. Cook, S. T. Moss, R. Chambers, G. Jenkins, R. J. Allen, L. V. Wain, I. Stewart, N. Oliver, D. L. Morganstein and J. K. Quint.“Association between hyperglycaemia, diabetes complications and development of fibrotic conditions among people living with type 1 and type 2 diabetes in England: a retrospective cohort study using UK Clinical Resource Datalink Aurum and Hospital Episode Statistics”.BMJ Open, 15(10): e103426.

2024

Mavroeidis, V. K., J. Knapton, F. Saffioti and D. L. Morganstein.“Pancreatic surgery and tertiary pancreatitis services warrant provision for support from a specialist diabetes team”.World J Diabetes, 15(4): 598-605.

2023

Percik R, Criseno S, Adam S, Young K and D. L. Morganstein.“Diagnostic criteria and proposed management of immune-related endocrinopathies following immune checkpoint inhibitor therapy for cancer”.Endocr Connect, 2023; 12: 2023/03/09. DOI: 10.1530/EC-22-0513.

2023

Mulla K, Farag S, Moore B, Matharu S, Young K, Larkin J, Popat S and D. L. Morganstein.“Hyperglycaemia following immune checkpoint inhibitor therapy—Incidence, aetiology and assessment”.Diabetic Medicine, 2023. DOI: 10.1111/dme.15053.

2023

Joharatnam-Hogan N and D. L. Morganstein.“Diabetes and cancer: Optimising glycaemic control”.J Hum Nutr Diet, 2023; 36: 504-513. 2022/06/25. DOI: 10.1111/jhn.13051.

2023

Hanson H, Durkie M, Lalloo F, Izatt L, McVeigh TP, Cook JA, Brewer C, Drummond J, Butler S, Cranston T, Casey R, Tan T, D. Morganstein, Eccles DM, Tischkowitz M, Turnbull C, Woodward ER, Maher ER and Centres UKCG.“UK recommendations for SDHA germline genetic testing and surveillance in clinical practice”.J Med Genet, 2023; 60: 107-111. 2022/03/10. DOI: 10.1136/jmedgenet-2021-108355.

2023

Cortellini A, D'Alessio A, Cleary S, Buti S, Bersanelli M, Bordi P, Tonini G, Vincenzi B, Tucci M, Russo A, Pantano F, Russano M, Stucci LS, Sergi MC, Falconi M, Zarzana MA, Santini D, Spagnolo F, Tanda ET, Rastelli F, Giorgi FC, Pergolesi F, Giusti R, Filetti M, Lo Bianco F, Marchetti P, Botticelli A, Gelibter A, Siringo M, Ferrari M, Marconcini R, Vitale MG, Nicolardi L, Chiari R, Ghidini M, Nigro O, Grossi F, De Tursi M, Di Marino P, Queirolo P, Bracarda S, Macrini S, Inno A, Zoratto F, Veltri E, Spoto C, Vitale MG, Cannita K, Gennari A, D. L. Morganstein, Mallardo D, Nibid L, Sabarese G, Brunetti L, Perrone G, Ascierto PA, Ficorella C and Pinato DJ.“Type 2 diabetes mellitus and efficacy outcomes from immune checkpoint blockade in patients with cancer”.Clinical Cancer Research, 2023. DOI: 10.1158/1078-0432.CCR-22-3116.

2021

Hayes AR, Crawford A, Al Riyami K, Tang C, Bomanji J, Baldeweg SE, Wild D, D. Morganstein, Harry A, Grozinsky-Glasberg S, Oleinikov K, Khoo B, Caplin ME, Nicolas GP and Grossman AB.“Metastatic Medullary Thyroid Cancer: The Role of 68Gallium-DOTA-Somatostatin Analogue PET/CT and Peptide Receptor Radionuclide Therapy”.J Clin Endocrinol Metab, 2021; 106: e4903-e4916. 2021/08/12. DOI: 10.1210/clinem/dgab588.

2021

Anderson B and D. L. Morganstein.“Endocrine toxicity of cancer immunotherapy: clinical challenges”.Endocr Connect, 2021; 10: R116-R124. 2021/02/06. DOI: 10.1530/EC-20-0489.

2021

Percik R, Larkin J and D. L. Morganstein.“Endocrinopathies induced by immune checkpoint inhibitors: the need for clear endocrine diagnosis”.Lancet Oncol, 2021; 22: 905-907. 2021/07/02. DOI: 10.1016/S1470-2045(21)00305-3.

2021

Nogueira E, Menon A, Dede A, Mitra I, Brock C, Larkin J and D. Morganstein.“Pituitary enlargement following ipilimumab without long term endocrine dysfunction”.Curr Probl Cancer, 2021: 100710. 2021/02/25. DOI: 10.1016/j.currproblcancer.2021.100710.

2020

Young, K., R. T. Lawlor, C. Ragulan, Y. Patil, A. Mafficini, S. Bersani, D. Antonello, D. Mansfield, S. Cingarlini, L. Landoni, A. Pea, C. Luchini, L. Piredda, N. Kannan, G. Nyamundanda, D. Morganstein, I. Chau, B. Wiedenmann, M. Milella, A. Melcher, D. Cunningham, N. Starling, A. Scarpa and A. Sadanandam.“Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours”.Gut, gutjnl-2020-2321.

2020

Siddiqui, M. S., Z. M. Lai, L. Spain, V. Greener, S. Turajlic, J. Larkin and D. L. Morganstein.“Predicting development of ipilimumab-induced hypophysitis: utility of T4 and TSH index but not TSH”.J Endocrinol Invest, 2020/05/26.

2020

Agarwal K, Yousaf N and D. Morganstein.“Glucocorticoid use and complications following immune checkpoint inhibitor use in melanoma”.Clin Med (Lond), 2020; 20: 163-168.

2019

Nogueira E, Newsom-Davis T and D. L. Morganstein.“Immunotherapy-induced endocrinopathies: assessment, management and monitoring”.Ther Adv Endocrinol Metab, 2019; 10: 2042018819896182.

2018

Higham, C. E., A. Olsson-Brown, P. Carroll, T. Cooksley, J. Larkin, P. Lorigan, D. Morganstein, P. J. Trainer and the Society for Endocrinology Endocrine Emergency Committee.“SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Acute management of the endocrine complications of checkpoint inhibitor therapy”.Endocrine Connections, 7(7): G1-G7.

2017

Paschou, S. A., A. D. Dede, P. G. Anagnostis, A. Vryonidou, D. Morganstein and D. G. Goulis.“Type 2 Diabetes and Osteoporosis: A Guide to Optimal Management”.J Clin Endocrinol Metab, 102(10): 3621-3634.

2017

Studer Bruengger, A. A., K. Wechalekar, R. Khattar, S. D. Rosen, J. L. Robertus, I. Chau, D. Morganstein, U. Rosendahl, A. Lyon and R. Mohiaddin.“Histologically Proven Myocardial Carcinoid Metastases: The Value of Multimodality Imaging”.Can J Cardiol, 33(10): 1336.e1339-1336.e1312.

2016

Morganstein, D. L., Z. Lai, L. Spain, et al..“Thyroid Abnormalities following the use of CTLA-4 and PD-1 Inhibitors in the treatment of melanoma”.Clin Endocrinol (Oxf), Epub ahead of publication.

2016

Khan KH, Wong M, Rihawi K, Bodla S, D. Morganstein, Banerji U, Molife LR.“Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management”.Oncologist, 2016; 21: 855-860.

2015

Balachandran K, Okines A, Gunapala R, D. Morganstein, Popat S.“Resolution of severe hyponatraemia is associated with improved survival in patients with cancer”.BMC Cancer, 2015; 15: 163.

2015

Young K, Iyer R, D. Morganstein, Chau I, Cunningham D, Starling N.“Pancreatic neuroendocrine tumors: a review”.Future Oncol (Lond), 2015; 11(5): 853-864.

2012

Morganstein D, Tan S, Gore M, Feher M.“Prevalence of diabetes in patients admitted to a cancer hospital”.The British Journal of Diabetes & Vascular Disease, 2012; 12(4): 178-180.

2010

Morganstein D, Wu P, Mane M, Fisk N, White R, Parker M.“Human fetal mesenchymal stem cells differentiate into brown and white adipocytes: a role for ERRalpha in human UCP1 expression”.Cell Res, 2010; 20(4): 434-444.

2009

Morganstein DL, Lewis DH, Jackson J, Isla A, Lynn J, Devendra D, et al..“The role of arterial stimulation and simultaneous venous sampling in addition to cross-sectional imaging for localisation of biochemically proven insulinoma”.Eur Radiol, 2009 Oct; 19(10): 2467-2473. PubMed PMID: 19597822.

2008

Hallberg M, Morganstein DL, Kiskinis E, Shah K, Kralli A, Dilworth SM et al..“A functional interaction between RIP140 and PGC-1alpha regulates the expression of the lipid droplet protein CIDEA”.Mol Cell Biol, 2008; 28(22): 6785-6795.

2008

Morganstein DL, Christian M, Turner JJ, Parker MG, White R.“Conditionally immortalized white preadipocytes: a novel adipocyte model”.J Lipid Res, 2008; 49(3): 679-685.

2007

White R, Morganstein D, Christian M, Seth A, Herzog B, Parker MG.“Role of RIP140 in metabolic tissues: Connections to disease”.FEBS Letters, 2007; 582(1): 39-45.

2007

Morganstein DL, Parker MG.“Role of nuclear receptor coregulators in metabolism”.Expert Review of Endocrinology and Metabolism, 2007; 2: 797-807.

2007

Debevec D, Christian M, Morganstein D, Seth A, Herzog B, Parker M et al..“Receptor Interacting Protein 140 regulates expression of Uncoupling Protein 1 in adipocytes through specific Peroxisome Proliferator Activated Receptor isoforms and Estrogen-Related Receptor”.Mol Endocrinol, 2007; 21(7): 1581-1592.

2005

Morganstein D, Mendoza N, Strickland N, Meeran K.“Low TSH in a patient with primary hypothyroidism”.J R Soc Med, 2005; 98(9): 417-418.

2005

Coll AP, Morganstein D, Jayne D, Soos MA, Rahilly S, Burke J.“Successful treatment of Type B insulin resistance in a patient with otherwise quiescent systemic lupus erythematosus”.Diabetic Medicine, 2005; 22(6): 814-815.

2002

Stephens JW, Morganstein DL, McLaughlin JE, Dorwood N, Vanderpump MP.“Isolated B-cell lymphoma of the pituitary region: a rare clinical entity”.Hosp Med, 2002; 63(5): 306-307.

2002

Holt S, Kingdon E, Morganstein D, Sweny P.“Simultaneous relapse of Graves' disease and minimal change glomerular disease”.Nephrol Dial Transplant, 2002; 17(4): 666-668.

1994

Binks, D. J., Grimes, R. W. and Morganstein, D. L..“Suppression of Zinc Interstitial Ion Migration in ZnO Due To The Presence of Sodium Ions”.Electroceramics, ed. Lee, W. E. and Bell, A., pub. Institute of Materials.